Skip to main content

Branded

  • Biogen Idec hopes treatment will be first advance in hemophilia B treatment in 15 years

    WESTON, Mass. — Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

    The drug maker announced that it had submitted a regulatory application for recombinant factor IX Fc fusion protein, or rFIXFc, which it called the first long-lasting factor IX therapy for hemophilia B.

  • Mintel: Declining user base means smoking cessation aids will experience slow growth through 2017

    CHICAGO — Sales of smoking cessation aids are projected to reach $1 billion in 2012 with continued growth driving sales as high as $1.2 billion by 2017, market research firm Mintel reported Thursday. 

  • March of Dimes highlights folic acid for pregnant women

    WHITE PLAINS, N.Y. — The March of Dimes is launching a campaign to encourage expectant mothers to take folic acid to prevent birth defects, the group said Friday.

    The group announced national Folic Acid Awareness Week, reminding pregnant women to take vitamin B. The vitamin is known to prevent birth defects like spina bifida and anencephaly, collectively known as neural tube defects. NTDs occur in the first few weeks following conception, often before a woman knows she is pregnant.

  • Bloomberg: B&L on sales block for as much as $10 billion

    NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion. 

    B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well. 

    Other companies who have been invited to bid include Merck and Pfizer. 

  • FDA approves new delivery method for MS drug

    NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

    Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.

  • Novo Nordisk appoints Curtis Oltmans as corporate VP, general counsel for legal and quality affairs

    PRINCETON, N.J. — Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

    In the new role, for which he will also join the company's U.S. executive team, Oltmans will be handle issues like law, quality, intellectual property, grants and philanthropy for the Danish drug maker's North American business.

  • Greenstone launches authorized generic Dilantin Infatabs

    PEAPACK, N.J. — Pfizer's generics division has launched an authorized generic drug for treating epilepsy.

    Greenstone announced the introduction of phenytoin tablets in the 50-mg strength, an authorized generic version of Pfizer's Dilantin Infatabs.

    Authorized generics are generic drugs marketed under their generic names at a reduced price, often through third-party companies under contract with the original drug's manufacturer.

  • Experimental ALS drug fails in trial

    WESTON, Mass. — An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said Thursday.

    Biogen announced results of its phase-3 trial of dexpramipexole in patients with the disease, known technically as amyotrophic lateral sclerosis, or ALS. The drug failed to improve functioning and survival in patients and failed to show efficacy in key secondary endpoints as well, the company said.

X
This ad will auto-close in 10 seconds